Statement of Principles concerning mesothelioma (Reasonable Hypothesis) (No. 41 of 2024)

“Reasonable hypothesis” is the core legal standard. Under section 120A of the VEA and section 338 of the MRCA, where a claim relates to operational service (or other kinds of “relevant service”), the decision-maker must determine whether there is a reasonable hypothesis connecting the injury or disease with the circumstances of service. The SoP specifies the minimum factors that can form such a hypothesis. If none of the factors is present, the hypothesis cannot be raised; if at least one factor exists and is related to service, the hypothesis is considered reasonable (subject to other evidentiary requirements). The concept is distinct from “reasonable satisfaction”, which applies to other service types.

“Relevant service” is defined in the dictionary as: operational service under the VEA; peacekeeping service under the VEA; hazardous service under the VEA; British nuclear test defence service under the VEA; warlike service under the MRCA; or non-warlike service under the MRCA. This means the SoP does not apply to claims based on peacetime service under the VEA (where the standard is reasonable satisfaction) or to service not within these categories.

“Mesothelioma” is defined by the instrument, not by the ICD-10-AM code alone. Subsection 7(2) gives a histological definition and specifically excludes certain tumours. The ICD-10-AM code C45 is noted but is not determinative; the definition in subsection 7(2) prevails. “Death from mesothelioma” includes death from a terminal event contributed to by mesothelioma (such as pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function).

The factors in section 9 each require a relationship to service. Factor 10 (inability to obtain appropriate clinical management) is the only factor that applies only to material contribution or aggravation of a pre-existing condition, as per subsection 10(2). This factor cannot be used to connect a new mesothelioma that arose out of service; it only applies where the person had mesothelioma before or during (but not arising out of) relevant service and the inability to obtain management worsened the condition.

The instrument uses specific concentration thresholds and latency periods. For example, factor 3 requires inhaling talc contaminated with asbestos fibres at “at least 5 weight percent”. Factor 4 requires fluoro-edenite fibres at “at least 1.76 fibres per litre” on more days than not for 5 years, with 20 years latency before clinical onset of pleural or peritoneal mesothelioma. Factor 5 requires erionite fibres at “at least 0.3 fibres per cubic centimetre” on more days than not for 5 years, with 20 years latency. Factor 6 requires a cumulative equivalent dose of at least 0.1 sievert, excluding normal background radiation. Factor 8 requires firefighting for at least 1,000 cumulative hours, with firefighting defined as “being involved in the direct combat of fires, including activities to control, extinguish, mop-up or prevent fires, or participating in training activities involving fires”. This is narrower than simply being a firefighter; it requires direct involvement in combatting fires.

The primary affected group is veterans and members of the Australian Defence Force who render “relevant service” as defined: operational service, peacekeeping service, hazardous service, British nuclear test defence service under the VEA, or warlike or non-warlike service under the MRCA. Any person who has served in these capacities and later develops mesothelioma (or dies from it) is potentially affected because their claim for compensation or other benefits under the VEA or MRCA will be assessed using this SoP. The instrument also affects the families and dependents of such veterans, who may be entitled to benefits upon death.

The instrument directly binds the Repatriation Medical Authority itself, as it sets the factors the RMA considers medically justified. It also binds the Department of Veterans’ Affairs (DVA) and the Veterans’ Review Board (VRB) in making decisions on claims. The DVA must ensure its delegates apply the factors. The VRB must apply the SoP when reviewing decisions. In practice, the instrument increases the compliance burden on DVA medical advisors and legal officers, who must be familiar with the new factors and definitions, especially the specific thresholds for asbestos exposure, talc contamination, fluoro-edenite and erionite concentrations, and the cumulative dose calculation for ionising radiation.

The instrument also affects medical practitioners who provide evidence in support of claims. They need to understand the latency periods and the requirement to relate each factor to service. For example, factor 8 (firefighting) requires proof of at least 1,000 hours of direct firefighting activity, which may require careful record keeping by the veteran or employer. The SoP may also affect private employers of firefighters who are veterans, as exposure records may be needed.

Claimants without legal or medical assistance may find the instrument burdensome. The precise thresholds for concentration and latency are not intuitive. The exclusion of peacetime service means a veteran who served only outside the defined categories cannot benefit from the reasonable hypothesis standard; they would need to meet the higher “reasonable satisfaction” test. The instrument could thus create an inequality of access to compensation based solely on the type of service.

The SoP creates no new duties directly on individuals. It imposes a duty on the Repatriation Medical Authority to determine factors based on sound medical-scientific evidence, which it has done. It also imposes a duty on decision-makers under the VEA and MRCA (whether DVA delegates or the VRB) to apply the SoP to claims. Section 120A of the VEA requires that, in determining a claim for operational service, a hypothesis connecting the injury or disease to service must be raised; if the SoP specifies factors, those factors must exist before the hypothesis is considered reasonable. The decision-maker must therefore consider whether any factor in section 9 is present and related to service.

The right of a claimant is to have their claim assessed in accordance with the SoP. If they can establish at least one factor (with evidence of latency, concentration, and relationship to service), the decision-maker cannot reject the claim on the basis that there is no reasonable hypothesis. However, the claimant still must prove the factor exists on the balance of probabilities? The standard of proof for factors is not explicitly stated in the instrument; it is a matter of general administrative law. Typically, the claimant must prove the factor exists to the reasonable satisfaction of the decision-maker (the civil standard) for the hypothesis to be considered reasonable. But the SoP only addresses the content of the hypothesis, not the standard of proof for the factors.

Another key right is that the SoP applies to claims under section 120A VEA and section 338 MRCA. Those provisions apply only to “relevant service”. A claimant has the right to have the decision-maker apply the correct SoP (the current one, not the repealed 2015 version). If the claimant’s exposure occurred after the relevant service ended, they must still show the factor existed at the time of clinical onset and relate it to service. The relationship requirement in section 10(1) means the factor must be connected to the service; for example, asbestos inhalation must have occurred during service.

The duty for claimants is to present sufficient evidence to satisfy the factor’s conditions. This may include exposure records, medical reports, and evidence of latency. The instrument itself does not specify a duty to provide information, but the VEA and MRCA contain obligations to provide documents and respond to requests.

The SoP does not create any penalties. It is a legislative instrument that defines a standard of proof for entitlement, not a regulatory prohibition. Enforcement mechanisms are found in the VEA and MRCA, which contain offences for making false or misleading statements in relation to claims (for example, under section 64 of the VEA). If a claimant knowingly provides false evidence to satisfy a factor (e.g., a false claim of firefighting hours), they could be prosecuted. Also, a medical practitioner who provides a fraudulent certificate could be liable.

The instrument itself cannot be “enforced” in the sense of compliance orders. Instead, its effect is that if a claim is decided without applying the correct SoP, the decision is likely wrong in law and may be set aside on review by the VRB or the Administrative Appeals Tribunal (AAT). There is no penalty for the decision-maker, but the claim may be remitted for reconsideration.

An important enforcement issue is the potential for the instrument to be neglected by decision-makers. If a DVA officer uses the old 2015 SoP after 23 July 2024, the decision would be invalid. The DVA must ensure all delegates are aware of the repeal and replacement. The RMA has no direct enforcement role; its function is to determine SoPs, not to monitor compliance.

The instrument also has implications for cost recovery. If a claim is wrongly rejected because the new factor (e.g., firefighting) was ignored, the veteran may have to pursue review, imposing stress and legal costs. The SoP could create incentive for DVA to carefully update its manuals, but that is administrative discipline, not a penalty.

The SoP is made under the VEA and also applies to the MRCA. It sits within a cascade of instruments. The VEA section 196B(2) gives the RMA power to determine SoPs for diseases and injuries. Section 120A of the VEA requires that a SoP must be applied in cases where a reasonable hypothesis standard applies. The MRCA section 338 has a similar effect. Therefore, the SoP interacts with the primary compensation legislation: it fills in the evidentiary content for the hypothesis test.

The SoP also interacts with other SoPs. Section 11 provides that if a factor in section 9 refers to an injury or disease covered by another SoP, the factors in that other SoP apply in accordance with its terms (as amended from time to time). For example, factor (2) requires “having asbestosis at the time of clinical onset”. Asbestosis has its own SoP (a separate instrument). That SoP will specify the factors for establishing asbestosis. So a claimant relying on factor (2) must also satisfy the elements of the asbestosis SoP. This cross-referencing adds another layer of evidentiary burden.

The SoP does not affect common law claims for damages against third parties (e.g., employers or manufacturers of asbestos). It only applies to claims under the VEA and MRCA. However, it may indirectly influence common law proceedings because veterans who receive compensation under the VEA or MRCA may have to repay those amounts from any common law damages under the compensation recovery provisions of the VEA. But the SoP itself does not deal with that.

The instrument repeals the previous SoP (No. 104 of 2015). This means any claim for mesothelioma that was not finally determined before 23 July 2024 must be assessed under the new SoP. For claims already determined, the new SoP has no retrospective effect unless a review is pending. The VEA provides mechanisms to vary decisions if a relevant SoP changes, but that is not in this instrument.

The dictionary defines “MRCA” and “VEA”, making clear which Acts are referenced. The definition of “relevant service” picks up specific service categories from both Acts. The interaction with the VEA and MRCA means that if a person has service under both Acts, the SoP applies to whichever service is relevant for the claim.

The instrument also references the ICD-10-AM classification, but only as a guide. The legal definition in subsection 7(2) overrides the code. This avoids problems if the ICD code changes.

The instrument is self-contained. It commences on 23 July 2024 and repeals the previous SoP (No. 104 of 2015, registered as F2015L01319). No other amendment history is provided in the text. The SoP is made by the RMA under subsections 196B(2) and (8) of the VEA, as in force at the date of making (21 June 2024). The VEA has been amended many times, but those amendments are not detailed here.

The 2015 SoP was the immediate predecessor. The RMA may have issued earlier SoPs for mesothelioma, but the text only references the one being repealed. The change from 2015 to 2024 reflects the RMA’s view that new medical-scientific evidence justifies updated factors, including new ones like firefighting and ventriculoperitoneal shunt. The notes in the dictionary for fluoro-edenite and erionite indicate the RMA considered geographic limitations on known cases. There is no indication of any transitional provisions for claims made before commencement but not yet determined. The application clause (section 5) simply says it applies to a claim to which section 120A or section 338 applies. That phrase is ambiguous: it could mean any claim that is subject to those sections, whether made before or after commencement, as long as it is not yet finally determined. However, section 4 repeals the old SoP, so from commencement the new SoP is the only one in force. The RMA could have included transitional provisions but did not.

Future amendments to the SoP will require a new determination. The instrument itself does not provide for automatic amendment or sunset.

The source text does not refer to any litigation. No cases are named. The SoP is new (commencing July 2024) and therefore no litigation under it has yet occurred. However, previous SoPs for mesothelioma have been the subject of judicial review and appeals to the AAT. Those cases often involve disputes over the interpretation of factors, latency periods, and whether scientific evidence supports a particular factor. For example, claimants have challenged whether asbestos inhalation required proof of visible dust or specific fibre counts. The new SoP attempts to clarify some of those issues by specifying concentrations (e.g., for talc contamination, fluoro-edenite, erionite). Litigants may still challenge the scientific soundness of the factors under section 196B(2) of the VEA, which requires the RMA to be satisfied on sound medical-scientific evidence. But that challenge would require attacking the RMA’s decision-making process, not the SoP itself on its face.

There is no mention of any court decision interpreting the 2015 SoP within the source. We cannot assume any. The safe approach is to note that the source contains no litigation history, and any previous interpretation is not binding on the new instrument. The RMA’s view that there is sound medical-scientific evidence is stated in section 8, but that is a statement of the Authority, not a judicial finding. If a person wishes to argue that the SoP is invalid for lack of evidence, they would likely need to bring proceedings in the Federal Court under the Administrative Decisions (Judicial Review) Act 1977 or the High Court’s original jurisdiction.

The note under the definition of erionite and fluoro-edenite mentions that confirmed cases have been restricted to certain regions (Turkey, Greece, Cyprus, Mexico for erionite; Sicily for fluoro-edenite). This could become a point of contention: if a veteran claims exposure in Australia, the scientific plausibility might be challenged. The RMA has included these factors anyway, indicating it considers the evidence sufficient regardless of geography.

Several details could trip up claimants and advisors. First, the definition of “firefighting” in factor 8 is limited to “direct combat of fires” and includes “training activities involving fires”. It does not include indirect activities such as fire investigation, vehicle maintenance, station duties, or administrative roles. A firefighter who spent most of their career on station without attending actual fires may not satisfy the 1,000 hour threshold. The cumulative period must be before clinical onset, with at least 10 years latency. This requires careful reconstruction of service history.

Second, the latency periods differ across factors. Asbestos inhalation requires at least 10 years; talc, fluoro-edenite, erionite, and ventriculoperitoneal shunt require 20 years; ionising radiation requires 5 years; firefighting requires 10 years. Failure to meet the latency period means the factor cannot be used, even if exposure was heavy. For example, a veteran who inhaled asbestos fibres only 8 years before diagnosis cannot rely on factor (1), even if exposure was enormous. The latency period starts from first inhalation, not from cumulative exposure.

Third, the definition of “cumulative equivalent dose” for ionising radiation excludes normal background radiation but includes “cosmic radiation at high altitude”. This could be relevant for Air Force personnel who flew frequently. However, the dose calculation must be to the affected region, and the unit is sievert. The instrument does not specify how to calculate cumulative dose for the pleura or peritoneum; that will likely require expert evidence.

Fourth, factor 10 (inability to obtain appropriate clinical management) applies only to material contribution or aggravation of pre-existing mesothelioma, and only where the mesothelioma was “suffered or contracted before or during (but did not arise out of) the person’s relevant service”. This is narrow. It cannot be used to establish a new case of mesothelioma due to service. If a person had mesothelioma from civilian exposure and then served, and their condition worsened because they could not get treatment during service, factor 10 might apply. But the worsening must be material and related to the inability.

Fifth, the cross-reference to other SoPs under section 11 means a claimant may need to satisfy two separate SoPs. For example, factor (2) requires asbestosis. The Asbestosis SoP may have its own latency periods and definitions. A claimant could have asbestosis established under that SoP but still need to prove the relationship to service for mesothelioma independent of the asbestosis.

Sixth, the definition of “relevant service” excludes peacetime service. A veteran who served only in peacetime and developed mesothelioma from exposure during that service cannot use the reasonable hypothesis standard; they would need to prove the claim on the balance of probabilities under section 120 VEA. This is a significant limitation.

Seventh, the instrument does not specify how to calculate the “cumulative period of at least 1,000 hours” for firefighting. Hours spent in training involving fires count, but what about time spent travelling to fires? The definition is narrow: “being involved in the direct combat of fires” and “training activities involving fires”. The DVA will have to issue guidance.

Eighth, the note for factor (4) says “inhaling fluoro-edenite fibres at a concentration of at least 1.76 fibres per litre”. This is an extremely low concentration (less than 2 fibres per litre). Proving historical exposure at such low levels is practically impossible without extensive personal air sampling. The factor is likely to be rarely used.

For a claimant, compliance with the SoP means gathering evidence to establish at least one factor from section 9 and showing it is related to relevant service. The first step is to identify which factor might apply. If the claimant was a firefighter, factor 8 may be most promising. They need to collate employment records, training records, and operational logs to demonstrate at least 1,000 cumulative hours of direct firefighting or training with fires. The latency of 10 years from the first firefighting activity to clinical onset must be satisfied. If the claimant worked with asbestos, they need to identify specific occasions when asbestos-containing material was applied, removed, dislodged, cut or drilled. The first inhalation must be at least 10 years before onset. Proof can include witness statements, work records, and medical evidence.

For factor 6 (ionising radiation), the claimant must show a cumulative equivalent dose of at least 0.1 sievert to the affected region, at least 5 years before onset. This requires retention of dosimetry records from occupational exposure (e.g., for radiologists, nuclear medicine workers, or defence personnel involved with nuclear tests). The dose calculation must exclude normal background but can include diagnostic radiation. For veterans of British nuclear tests, records may be available from the UK Ministry of Defence or the Australian Defence Force.

Claimants seeking to rely on factor 3 (talc contaminated with asbestos) must prove the talc had at least 5 weight percent asbestos fibres. This is a very high contamination level; most commercial talc is below that. Claimants would need to identify the specific source and likely obtain testing or historical data.

For factor 9 (ventriculoperitoneal shunt), the claimant needs medical records showing the shunt was inserted for hydrocephalus at least 20 years before peritoneal mesothelioma diagnosis. This is a rare factor but straightforward with medical records.

Legal advisors should check that the claim falls within the definition of “relevant service”. If the person served only in peacetime under the VEA, the SoP does not apply; the claim must be assessed under the different standard. In that case, the advisor must argue the case on the balance of probabilities without the benefit of the SoP’s specified factors.

DVA compliance requires that all decision-makers are trained on the new SoP and apply it to all claims from 23 July 2024. DVA should update internal guidance tools, such as the Principles of Review and the Delegations Manual. DVA must also ensure that medical officers are aware of the new factors and the need to consider evidence of firefighting hours and ventriculoperitoneal shunts.

For medical assessors, they must verify latency periods. For example, a mesothelioma diagnosis at age 55 with asbestos exposure at age 20 (35 years before) satisfies the 10 year rule. But if exposure was at age 55 and diagnosis at age 56, latency fails. Ensuring accurate exposure timing is critical.

Advisors should also note the possibility of claiming under both the VEA and MRCA if the veteran has both operational and warlike service. The SoP applies to both, but the claim must specify which service type is relied on.

Finally, if the claim relies on factor 10, the veteran must show the mesothelioma existed before or during service (but not arising out of service) and that they could not obtain appropriate clinical management for it, and that this materially contributed to worsening. This is complex and will require medical evidence of the natural history of the disease and what management was available but not provided. The factor is likely to be rarely successful.